123 related articles for article (PubMed ID: 30840759)
1. Clinical and Molecular Characterization of Adult Glioblastomas in Southern Brazil.
Trevisan P; Graziadio C; Rodrigues DBK; Rosa RFM; Soares FP; Provenzi VO; de Oliveira CAV; Paskulin GA; Varella-Garcia M; Zen PRG
J Neuropathol Exp Neurol; 2019 Apr; 78(4):297-304. PubMed ID: 30840759
[TBL] [Abstract][Full Text] [Related]
2. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
3. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.
Nobusawa S; Stawski R; Kim YH; Nakazato Y; Ohgaki H
Neuropathology; 2011 Dec; 31(6):583-8. PubMed ID: 21382095
[TBL] [Abstract][Full Text] [Related]
4. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.
Rodriguez FJ; Scheithauer BW; Giannini C; Bryant SC; Jenkins RB
Cancer; 2008 Nov; 113(10):2779-89. PubMed ID: 18816605
[TBL] [Abstract][Full Text] [Related]
5. Copy Number Profiling of Brazilian Astrocytomas.
Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
[TBL] [Abstract][Full Text] [Related]
6. Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.
Koshiyama DB; Trevisan P; Graziadio C; Rosa RFM; Cunegatto B; Scholl J; Provenzi VO; de Sá AP; Soares FP; Velho MC; de A P Filho N; Oliveira CA; Zen PRG
J Neurooncol; 2017 Dec; 135(3):465-472. PubMed ID: 28856550
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
8. PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance.
Carlotto BS; Trevisan P; Provenzi VO; Soares FP; Rosa RFM; Varella-Garcia M; Zen PRG
Neuromolecular Med; 2023 Sep; 25(3):441-450. PubMed ID: 37610648
[TBL] [Abstract][Full Text] [Related]
9. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
[TBL] [Abstract][Full Text] [Related]
11. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
12. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
13. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
14. Molecular heterogeneity of glioblastomas: does location matter?
Denicolaï E; Tabouret E; Colin C; Metellus P; Nanni I; Boucard C; Tchoghandjian A; Meyronet D; Baeza-Kallee N; Chinot O; Figarella-Branger D
Oncotarget; 2016 Jan; 7(1):902-13. PubMed ID: 26637806
[TBL] [Abstract][Full Text] [Related]
15. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
[TBL] [Abstract][Full Text] [Related]
16. Amplification of the epidermal growth factor receptor gene in glioblastoma: an analysis of the relationship between genotype and phenotype by CISH method.
Miyanaga T; Hirato J; Nakazato Y
Neuropathology; 2008 Apr; 28(2):116-26. PubMed ID: 18021194
[TBL] [Abstract][Full Text] [Related]
17. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.
Giannini C; Sarkaria JN; Saito A; Uhm JH; Galanis E; Carlson BL; Schroeder MA; James CD
Neuro Oncol; 2005 Apr; 7(2):164-76. PubMed ID: 15831234
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity on chromosome 10q in glioblastomas, and its association with other genetic alterations and survival in Indian patients.
Kakkar A; Suri V; Jha P; Srivastava A; Sharma V; Pathak P; Sharma MC; Sharma MS; Kale SS; Chosdol K; Phalak M; Sarkar C
Neurol India; 2011; 59(2):254-61. PubMed ID: 21483128
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of human glioblastomas using a genomic microarray system.
Suzuki T; Maruno M; Wada K; Kagawa N; Fujimoto Y; Hashimoto N; Izumoto S; Yoshimine T
Brain Tumor Pathol; 2004; 21(1):27-34. PubMed ID: 15696966
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
